Story of Influenza Antivirals: Part 31

The FDA and CDC split, compliharms and follow-up

We have already seen that the FDA’s refusal to allow claims of the effect of either antiviral against influenza complications and transmission was based on the assessment of clinical study reports. Consequently, the whole pandemic rationale for stockpiling was called into question.

However, other branches of the US Government, the WHO and most European p…